GAITHERSBURG, Md., Oct. 10, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. ALT, a clinical-stage biopharmaceutical company, today announced that management will participate in the following investor conferences during the months of October and November:
| H.C. Wainwright 3rd Annual NASH Investor Conference | ||
| Date: Time: Speaker: Location: Webcast: | Monday, October 21 11:20am ET M. Scott Harris M.D., Chief Medical Officer St. Regis Hotel, New York City https://ir.altimmune.com/investors/events-and-presentations | |
| BIO Investor Forum | ||
| Date: Time: Speaker: Location: Webcast: | Wednesday, October 23 12:45pm ET/9:45am PT Vipin K. Garg Ph. D., President and Chief Executive Officer Westin St. Francis Hotel, San Francisco, CA https://ir.altimmune.com/investors/events-and-presentations | |
| Jefferies 2019 London Healthcare Conference | ||
| Date: Attendees: Location: | November 20 and November 21 (one-on-one meetings only) Vipin K. Garg Ph.D., President and Chief Executive Officer Will Brown, Chief Financial Officer Waldorf Hilton, London, UK | |
About Altimmune
Altimmune is a clinical stage biopharmaceutical company focused on developing treatments for liver diseases and immune modulating therapies. The Company's diverse pipeline includes next generation peptide therapeutics for NASH (ALT-801) and chronic Hepatitis B (HepTcellTM), conjugated immunostimulants for the treatment of cancer (ALT-702) and intranasal vaccines (NasoShieldTM and NasoVAXTM). For more information on Altimmune, please visit www.altimmune.com.
| Contacts | |
| Will Brown | Ashley R. Robinson |
| Chief Financial Officer | Managing Director LifeSci Advisors |
| Phone: 240-654-1450 | Phone: 617-535-7742 |
| Email: wbrown@altimmune.com | Email: arr@lifesciadvisors.com |
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
